RxDoctor Payments Data

Tracy Neilan, NP

Family · Ladson, SCNPI 1639462591

Payments from drug & device makers

$4,131in general payments, 2019–2025

Across 101 payments — averaging $40.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • AbbVie$269
  • Abbott$223
  • Kyowa Kirin, Inc.$222
  • Novo Nordisk$187
  • Amneal Pharmaceuticals LLC$177
  • plus $1K from 22 others

What the payments were for

  • Travel & lodging$1,38934%
  • Food & beverage$2,59863%
  • Education$1443%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,131 in reported general payments places this provider in the 90th percentile of 3,248 family providers in South Carolina.

See all family providers in South Carolina

Medicare billing

Part B allowed, 2024
$79,058
Medicare patients
580
Services billed
1,445

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RytaryCarbidopa/Levodopa185$409,632
GocovriAmantadine Hcl78$254,720
IngrezzaValbenazine Tosylate30$166,769
NuplazidPimavanserin Tartrate21$138,791
NourianzIstradefylline61$132,333
Austedo XrDeutetrabenazine17$116,248
InbrijaLevodopa32$66,844
Droxidopa12$64,095
Carbidopa-LevodopaCarbidopa/Levodopa565$31,920
Rasagiline Mesylate75$17,883
MyrbetriqMirabegron26$17,645
Carbidopa-Levodopa ErCarbidopa/Levodopa230$9,788
Carbidopa37$9,731
Rivastigmine45$6,649
AmantadineAmantadine Hcl77$4,171

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Amneal Pharmaceuticals LLCRytary$177$409,632185 claims
Kyowa Kirin, Inc.Nourianz$222$132,33361 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$148$116,24817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,248 family providers in South Carolina.

Other family in Ladson

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →